Perceived compliance and barriers to care in sublingual immunotherapy

Kumar, Meghan Bruce; Oh, Melissa S.; Leader, Brittany A.; Rotella, Melissa; Stillman, Leisa; DelGaudio, John M.; Wise, Sarah K.

doi:10.1002/alr.21920

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Common reasons for SLIT discontinuation included cost, improvement of symptoms without treatment, perceived lack of effectiveness, and inconvenience. 7,9 In regard to cost, aqueous SLIT is typically not covered by health insurance plans in the United States (U.S.). 10,11 In contrast, the cost of SCIT is largely dependent on the patient's insurance plan.…”

Section: Introductionmentioning

confidence: 99%

Predictors of Completion of Sublingual Immunotherapy

et al. 2020

View full text Add to dashboard Cite

Objectives: Sublingual immunotherapy (SLIT) has emerged as an effective treatment alternative to subcutaneous immunotherapy (SCIT) given its improved safety profile and more convenient dosing. However, SLIT still relies on daily dosing for many years to optimize effectiveness. This study sought to investigate factors that influence patient completion of SLIT.Methods: We performed an institutional retrospective review of patients who received SLIT (2008SLIT ( -2020. Completion was defined as completing at least 36 months of SLIT. Patient demographics and characteristics, including the number of allergens treated, history of asthma and sinus surgery, number of clinic visits, and total time undergoing SLIT, were documented. Multivariate models were used to analyze predictors of SLIT completion. Subgroup analysis was performed among pediatric patients and patients who discontinued SLIT.Results: Of the 404 total patients, 249 (61.6%) discontinued, 47 (11.6%) completed, and 108 (26.7%) were currently undergoing SLIT. The mean duration of therapy was 11.2 months for those who discontinued and 49.4 months for patients who completed SLIT. The odds of SLIT completion were twice as high with each additional clinic visit (P < .001), and twice as high when the dosage was increased during therapy (P = .06). Pediatric patients younger than age 12 with a history of asthma were over five times more likely to complete therapy (P = .045). Patients with more clinic visits (P < .001) and higher associated costs (P = .003) were less likely to be lost to follow-up.Conclusion: Increasing the frequency of clinic visits, improving therapy availability, and mitigating concerns about clinical efficacy may increase patient completion of SLIT.

show abstract

Section: Introductionmentioning

confidence: 99%

Predictors of Completion of Sublingual Immunotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This Nrf2 antioxidant pathway has been shown to reduce allergic asthma in a mice model and now, for the first time has been shown to have similar effect in an allergic rhinitis model. A retrospective study by Kumar et al . of aqueous sublingual immunotherapy revealed that patients perceived their treatment compliance to be excellent even when their providers did not consider their compliance to be excellent.…”

mentioning

confidence: 99%